Vasomotor Symptoms

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found

By MedXY 05/13/2026

A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.

Cardiology news

Hormone Therapy for Hot Flashes: Safe and Effective for Women 50–59, Harm Signals After Age 70 — New WHI Secondary Analysis Clarifies Cardiovascular Risk by Age

By MedXY 11/18/2025

A WHI secondary analysis finds that oral conjugated estrogens (with or without MPA) relieve vasomotor symptoms in women 50–59 without clear ASCVD harm, but starting HT in women ≥70 is associated with increased atherosclerotic cardiovascular disease.

Clinical Updates news OB/GYN & Women's Health

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

By MedXY 11/13/2025

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.

news OB/GYN & Women's Health

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

By MedXY 11/13/2025

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.

OB/GYN & Women's Health

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY 10/24/2025

Bayer's Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety in phase 3 trials.

OB/GYN & Women's Health Specialties

Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study

By MedXY 08/22/2025

The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reproductive stages.

OB/GYN & Women's Health Oncology Specialties

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

AI news OB/GYN & Women's Health Specialties

Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials

By MedXY 08/20/2025

This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.

news OB/GYN & Women's Health Specialties

FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms

By MedXY 07/28/2025

The FDA delays its review of Bayer's elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.